Volume Alert - ARNA 4.81 Arena Pharmaceuticals $AR
Post# of 71
Posted On: 11/13/2014 1:09:51 PM
Volume Alert - ARNA 4.81 Arena Pharmaceuticals $ARNA Hit a high today of 4.90 Closing the day 10:30 at 4.81 +0.11 +2.34% With a day low of 4.74 and a total volume of 1,600,138.
ARNA Recent Posts: http://investorshangout.com/Arena-Pharmaceuti...RNA-53369/
ARNA Arena Pharmaceuticals Recent Headline News
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST
OREX: 5.99 (+0.15), HLF: 38.03 (+0.22), NVO: 44.02 (-0.30), VVUS: 3.36 (+0.02), AMGN: 160.78 (-1.15), GSK: 45.60 (-0.02), ARNA: 4.75 (+0.05)
Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 13, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time), at The New York Palace Hotel in New York.
ARNA: 4.75 (+0.05)
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:27AM CST
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
ARNA: 4.75 (+0.05)
Arena Pharmaceuticals' (ARNA) Presents at Credit Suisse Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 9:32PM CST
ARNA: 4.75 (+0.05)
Bel-Phen Pilot Study News, Hold On To Your Shares
Rx Stocks - at Seeking Alpha - Tue Nov 11, 12:13PM CST
OREX: 5.99 (+0.15), VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals ' Belviq and VIVUS 's Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.40 (-0.02), VVUS: 3.36 (+0.02), GSK: 45.60 (-0.02), ARNA: 4.75 (+0.05)
Why Orexigen Therapeutics, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 10, 5:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 5.99 (+0.15), VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 12:24PM CST
OREX: 5.99 (+0.15), VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.99 (+0.15), VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST
VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST
OREX: 5.99 (+0.15), VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST
VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
PR Newswire - Thu Nov 06, 7:00AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 7-11, 2014, in Boston, Massachusetts.
ARNA: 4.75 (+0.05)
Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
PR Newswire - Wed Nov 05, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014, at 3:00 p.m. Mountain Time (5:00 p.m. Eastern Time), at The Arizona Biltmore in Phoenix, Arizona.
ARNA: 4.75 (+0.05)
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:30AM CST
Arena Pharmaceuticals (ARNA) reported a net loss of 13 cents per share in the third quarter of 2014 in line with the Zacks Consensus Estimate.
VVUS: 3.36 (+0.02), AMAG: 34.62 (-0.31), ARNA: 4.75 (+0.05)
Orexigen's Contrave Has Modest Start
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:30PM CST
OREX: 5.99 (+0.15), ARNA: 4.75 (+0.05)
Arena Beats The Street On Taigen Stock Sale
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:26PM CST
ARNA: 4.75 (+0.05)
Arena Pharmaceuticals' (ARNA) CEO Jack Lief on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 11:53AM CST
ARNA: 4.75 (+0.05)
Arena Pharmaceuticals (ARNA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 03, 7:25AM CST
ARNA: 4.75 (+0.05)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 104.88 (-2.02), CLVS: 57.44 (-1.00), ARWR: 6.36 (-0.17), ACHN: 13.98 (-0.87), MRK: 59.47 (+0.16), RTRX: 11.78 (+0.22), RGLS: 18.25 (-1.37), EPZM: 22.58 (-1.30), AGIO: 87.00 (+0.13), RMTI: 11.13 (-0.11), ARNA: 4.75 (+0.05), KERX: 15.63 (+0.04)
ARNA Recent Posts: http://investorshangout.com/Arena-Pharmaceuti...RNA-53369/
ARNA Arena Pharmaceuticals Recent Headline News
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST
OREX: 5.99 (+0.15), HLF: 38.03 (+0.22), NVO: 44.02 (-0.30), VVUS: 3.36 (+0.02), AMGN: 160.78 (-1.15), GSK: 45.60 (-0.02), ARNA: 4.75 (+0.05)
Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 13, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time), at The New York Palace Hotel in New York.
ARNA: 4.75 (+0.05)
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:27AM CST
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
ARNA: 4.75 (+0.05)
Arena Pharmaceuticals' (ARNA) Presents at Credit Suisse Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 9:32PM CST
ARNA: 4.75 (+0.05)
Bel-Phen Pilot Study News, Hold On To Your Shares
Rx Stocks - at Seeking Alpha - Tue Nov 11, 12:13PM CST
OREX: 5.99 (+0.15), VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals ' Belviq and VIVUS 's Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.40 (-0.02), VVUS: 3.36 (+0.02), GSK: 45.60 (-0.02), ARNA: 4.75 (+0.05)
Why Orexigen Therapeutics, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 10, 5:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 5.99 (+0.15), VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 12:24PM CST
OREX: 5.99 (+0.15), VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.99 (+0.15), VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST
VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST
OREX: 5.99 (+0.15), VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST
VVUS: 3.36 (+0.02), ARNA: 4.75 (+0.05)
Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
PR Newswire - Thu Nov 06, 7:00AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 7-11, 2014, in Boston, Massachusetts.
ARNA: 4.75 (+0.05)
Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
PR Newswire - Wed Nov 05, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014, at 3:00 p.m. Mountain Time (5:00 p.m. Eastern Time), at The Arizona Biltmore in Phoenix, Arizona.
ARNA: 4.75 (+0.05)
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:30AM CST
Arena Pharmaceuticals (ARNA) reported a net loss of 13 cents per share in the third quarter of 2014 in line with the Zacks Consensus Estimate.
VVUS: 3.36 (+0.02), AMAG: 34.62 (-0.31), ARNA: 4.75 (+0.05)
Orexigen's Contrave Has Modest Start
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:30PM CST
OREX: 5.99 (+0.15), ARNA: 4.75 (+0.05)
Arena Beats The Street On Taigen Stock Sale
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:26PM CST
ARNA: 4.75 (+0.05)
Arena Pharmaceuticals' (ARNA) CEO Jack Lief on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 11:53AM CST
ARNA: 4.75 (+0.05)
Arena Pharmaceuticals (ARNA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 03, 7:25AM CST
ARNA: 4.75 (+0.05)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 104.88 (-2.02), CLVS: 57.44 (-1.00), ARWR: 6.36 (-0.17), ACHN: 13.98 (-0.87), MRK: 59.47 (+0.16), RTRX: 11.78 (+0.22), RGLS: 18.25 (-1.37), EPZM: 22.58 (-1.30), AGIO: 87.00 (+0.13), RMTI: 11.13 (-0.11), ARNA: 4.75 (+0.05), KERX: 15.63 (+0.04)
(0)
(0)